Kayla Steele, MD
Interventional Pain Medicine · Sewell, NJNPI 1184019226
Payments from drug & device makers
What this record shows
Nevro Corp. accounts for 82.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $2,266 and has fallen 93.6% since, to $145 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in NJ, where the typical reported total is $3,760.
Across 32 payments — averaging $107.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$3K
- Medtronic$246
- Nalu Medical, Inc.$149
- Boston Scientific$88
- Si-bone, Inc.$86
- Abbott$26
What the payments were for
- Travel & lodging$1,41641%
- Food & beverage$2,00959%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 24 | $2,830 |
| Medtronic(2 entities) | 3 | $246 |
| Nalu Medical, Inc. | 1 | $149 |
| Boston Scientific | 1 | $88 |
| Si-bone, Inc. | 2 | $86 |
| Abbott | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,425 in reported general payments places this provider in the 45th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 294 | $1,648 |
| Tizanidine Hcl | 198 | $999 |
| Methylprednisolone | 34 | $213 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Sewell
- Malini KhannaSewell$6K
- Connor McElligottSewell$4K
- Youssef JosephsonWest Deptford$496K
- Ali ValimahomedHolmdel$415K
- Saurabh DangEdgewater$157K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Steve AydinFranklin Lakes$22K
- Kieran SlevinHainesport$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.